AR(Acetyl-K631) Polyclonal Antibody
活动价:
市场价:¥880.00
- 50μL
- 100μL
FAB2600334
- 产品信息
商品描述
靶点-Target
Androgen Receptor
反应性
Human:K631,Mouse:K610,Rat:K613
应用
WB,ELISA
宿主物种-Host Species
Rabbit
同种型-Isotype
IgG
修饰-Modification
Acetyl
MW(Calculated)
99kD
推荐稀释比
WB 1:500-1:2000;ELISA 1:20000;Not yet tested in other applications.
组成
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
纯化工艺
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
储存
-15°C to -25°C/1 year(Do not lower than -25°C)
浓度
1 mg/ml
克隆性
Polyclonal
免疫原
Synthesized Acetyl peptide derived from human AR. at AA range: K631
特异性
This antibody detects endogenous levels of ARat Human:K631;Mouse:K610;Rat:K613, It doesn't reacte with total protein.
基因名称
AR DHTR NR3C4
蛋白名称
AR
别名
Androgen receptor;Dihydrotestosterone receptor;Nuclear receptor subfamily 3 group C member 4;
Organism-1
Human
基因ID-1
367
SwissProt-1
P10275
Organism-2
Mouse
SwissProt-2
P19091
背景
The androgen receptor gene is more than 90 kb long and codes for a protein that has 3 major functional domains: the N-terminal domain, DNA-binding domain, and androgen-binding domain. The protein functions as a steroid-hormone activated transcription factor. Upon binding the hormone ligand, the receptor dissociates from accessory proteins, translocates into the nucleus, dimerizes, and then stimulates transcription of androgen responsive genes. This gene contains 2 polymorphic trinucleotide repeat segments that encode polyglutamine and polyglycine tracts in the N-terminal transactivation domain of its protein. Expansion of the polyglutamine tract from the normal 9-34 repeats to the pathogenic 38-62 repeats causes spinal bulbar muscular atrophy (Kennedy disease). Mutations in this gene are also associated with complete androgen insensitivity (CAIS). Two alternatively spliced variants encoding distinct isoform
细胞定位
Nucleus . Cytoplasm . Detected at the promoter of target genes (PubMed:25091737). Predominantly cytoplasmic in unligated form but translocates to the nucleus upon ligand-binding. Can also translocate to the nucleus in unligated form in the presence of RACK1. .





